News

The professor of neurosciences and head of neuropsychology at Fleni Institute in Buenos Aires, Argentina, discussed findings from the LatAm-FINGERS study that suggest structured, multidomain lifestyle interventions may offer meaningful cognitive benefits among older adults in Latin America. [WATCH TIME: 3 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is tau-targeting therapies for Alzheimer disease!

A 12-week, placebo-controlled phase 2 trial found that an oral THC/CBD combination significantly reduced agitation in hospice-eligible patients with Alzheimer disease and other dementias, meeting its primary and key secondary endpoints.

Joey English, MD, Chief Medical Officer of Route 92 Medical, discusses the company's reperfusion platform, the goals of the SUMMIT RISE real-world evidence study, and what vessel-matched catheter technology could mean for acute ischemic stroke care.

Neurology News Network for the week ending July 26th, 2026. [WATCH TIME: 5 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 24, 2026.

Yogesh Shah, MD, explains the biological basis of P-tau217 and why blood-based biomarker testing is emerging as a practical, highly accurate tool for identifying Alzheimer's pathology.

Andrew Lee, MD, PhD, cofounder and CEO of Spot Biosystems, discusses the company's extracellular vesicle platform, the first non-viral delivery of full-length dystrophin in patients with Duchenne muscular dystrophy.

Epilepsy expert Susan Duberstein, MD, explores how multidisciplinary neurocutaneous clinics improve diagnosis, surveillance, care coordination, and long-term outcomes for patients with complex neurocutaneous syndromes.

Stephen Williams, PhD, chief scientific officer of Alamar Biosciences, discusses the potential of eMTBR-tau measurement, multiplex biomarker testing, and AI-driven approaches to improve the characterization of Alzheimer disease and its coexisting pathologies.

The submission is backed by phase 3 FoCus trial data showing ALXN1840 tripled copper mobilization and produced significant, sustained neurologic improvement compared with standard of care over 48 weeks.

Kristen Harris, MD, Medical Director of the Extended Recovery Unit at Hackensack Meridian JFK Johnson Rehabilitation Institute, discussed new findings on functional recovery and community discharge rates in acquired brain injury patients undergoing skilled nursing facility rehabilitation.

At AAIC 2026, the head of sciences at the Alzheimer Center Amsterdam, discusses the growing role of biomarkers in understanding the biological complexity of Alzheimer disease and advancing more personalized approaches to diagnosis and treatment. [WATCH TIME: 3 minutes]

Spinogenix’s codabakalner, an investigational BK channel modulator, is currently being evaluated in CLARITY, a phase 2b/3 trial for the treatment of patients with Fragile X syndrome.

Ahead of World Brain Day, NeurologyLive explores 5 emerging strategies for preventing neurologic disease, from modifiable dementia risk factors to GLP-1 drugs, sleep science, the gut brain axis, and wearable technology.

A look at where things stand for Fragile X syndrome drug development, covering seven agents across four mechanisms as the field regroups from two recent Phase 3 setbacks.

In honor of Fragile X Syndrome Awareness Day, held annually on July 22, the professor of psychiatry at Cincinnati Children's Hospital outlined where testing for the disorder still falls short. [WATCH TIME: 6 minutes]

Brett Morrison, MD, PhD, associate professor at Johns Hopkins University, recaps his PNS 2026 presentation on current and emerging biomarkers in peripheral nerve disease, from neurofilament light chain to muscle MRI and microRNA.

From concussion recognition to blood-based biomarkers and the long-term effects of repetitive heading, neurologists discuss how emerging research is changing the understanding of brain injury in the world's most popular sport.

From concussion recognition to blood-based biomarkers and the long-term effects of repetitive heading, neurologists discuss how emerging research is changing the understanding of brain injury in the world's most popular sport.

At SLEEP 2026, the head of orexin franchise development and neuroscience programs at Takeda discussed new phase 3 data for oveporexton in patients with narcolepsy type 1. [WATCH TIME: 5 minutes]

At SLEEP 2026, the research intern at Beth Israel Deaconess Medical Center described the development of an electronic health record–based machine learning model for obstructive sleep apnea screening. [WATCH TIME: 3 minutes]

Laura Nisenbaum, PhD, Interim Chief Science Officer at the Alzheimer's Drug Discovery Foundation, shares her perspective on the FDA's approval of a subcutaneous starting dose for lecanemab and what it means for access, clinical practice, and the future of Alzheimer disease treatment.

The FDA granted priority review to zeleciment rostudirsen for exon 51-amenable Duchenne muscular dystrophy, with a PDUFA target action date of January 21, 2027.

Understanding how amyloid pathology develops years before symptoms emerge is essential to appreciating the growing role of blood-based biomarkers in earlier Alzheimer disease detection.

The $100 million PROTECT-Cog trial will test whether adding a GLP-1 drug to the proven U.S. POINTER lifestyle intervention further cuts dementia risk in at-risk older adults.

Here's some of what is coming soon to NeurologyLive® this week.

PrevenTRON, a study of trontinemab, will enroll 1600 cognitively unimpaired participants identified by elevated plasma p-tau217, using time to clinical progression as the primary endpoint.